Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treprostinil liposomal - Pharmosa BioPharm

Next Previous
Drug Profile

Treprostinil liposomal - Pharmosa BioPharm

Alternative Names: L-606; liposomal treprostinil controlled release - Pharmosa BioPharm; liposomal treprostinil sustained release - Pharmosa BioPharm

Latest Information Update: 28 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmosa Biopharm
  • Class Acetic acids; Antifibrotics; Antihypertensives; Antineoplastics; Cyclopentanes; Heart failure therapies; Naphthalenes; Prostaglandins; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pulmonary arterial hypertension
  • Phase I Pulmonary hypertension

Most Recent Events

  • 28 Jul 2025 No recent reports of development identified for phase-I development in Pulmonary-hypertension(In volunteers) in Taiwan (Inhalation, Liposomal)
  • 27 Mar 2025 3892164 - Deal Updated
  • 17 May 2024 Adverse events data from a phase III trial in Pulmonary arterial hypertension presented at the 120th International Conference of the American Thoracic Society (ATS-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top